These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19028932)

  • 1. Energy absorption is reduced with oleic acid supplements in human short bowel syndrome.
    Compher CW; Kinosian BP; Rubesin SE; Ratcliffe SJ; Metz DC
    JPEN J Parenter Enteral Nutr; 2009; 33(1):102-8. PubMed ID: 19028932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ghrelin does not predict adaptive hyperphagia in patients with short bowel syndrome.
    Compher CW; Kinosian BP; Metz DC
    JPEN J Parenter Enteral Nutr; 2009; 33(4):428-32. PubMed ID: 19176401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slowing of gastrointestinal transit by oleic acid: a preliminary report of a novel, nutrient-based treatment in humans.
    Lin HC; van Citters GW; Heimer F; Bonorris G
    Dig Dis Sci; 2001 Feb; 46(2):223-9. PubMed ID: 11281167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of octreotide, soy polysaccharide, codeine and loperamide on nutrient, fluid and electrolyte absorption in the short-bowel syndrome.
    Rodrigues CA; Lennard-Jones JE; Thompson DG; Farthing MJ
    Aliment Pharmacol Ther; 1989 Apr; 3(2):159-69. PubMed ID: 2491467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of glutamine in short-bowel syndrome.
    Scolapio JS; McGreevy K; Tennyson GS; Burnett OL
    Clin Nutr; 2001 Aug; 20(4):319-23. PubMed ID: 11478829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.
    Jeppesen PB; Hartmann B; Thulesen J; Graff J; Lohmann J; Hansen BS; Tofteng F; Poulsen SS; Madsen JL; Holst JJ; Mortensen PB
    Gastroenterology; 2001 Mar; 120(4):806-15. PubMed ID: 11231933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study.
    Madsen KB; Askov-Hansen C; Naimi RM; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
    Regul Pept; 2013 Jun; 184():30-9. PubMed ID: 23511332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study.
    Jeppesen PB; Szkudlarek J; Høy CE; Mortensen PB
    Scand J Gastroenterol; 2001 Jan; 36(1):48-54. PubMed ID: 11218239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study.
    Scolapio JS; Camilleri M; Fleming CR; Oenning LV; Burton DD; Sebo TJ; Batts KP; Kelly DG
    Gastroenterology; 1997 Oct; 113(4):1074-81. PubMed ID: 9322500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.
    Naimi RM; Hvistendahl M; Enevoldsen LH; Madsen JL; Fuglsang S; Poulsen SS; Kissow H; Pedersen J; Nerup N; Ambrus R; Achiam MP; Svendsen LB; Holst JJ; Hartmann B; Hansen SH; Dragsted LO; Steensberg A; Mouritzen U; Hansen MB; Jeppesen PB
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):354-363. PubMed ID: 30880176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone enhances fat-free mass and glutamine availability in patients with short-bowel syndrome: an ancillary double-blind, randomized crossover study.
    Seguy D; Darmaun D; Duhamel A; Thuillier F; Cynober L; Cortot A; Gottrand F; Messing B
    Am J Clin Nutr; 2014 Sep; 100(3):850-8. PubMed ID: 25080462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study.
    Szkudlarek J; Jeppesen PB; Mortensen PB
    Gut; 2000 Aug; 47(2):199-205. PubMed ID: 10896910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjugated bile acid replacement therapy for short-bowel syndrome.
    Gruy-Kapral C; Little KH; Fordtran JS; Meziere TL; Hagey LR; Hofmann AF
    Gastroenterology; 1999 Jan; 116(1):15-21. PubMed ID: 9869597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 'ileal brake' after ileal pouch-anal anastomosis.
    Soper NJ; Chapman NJ; Kelly KA; Brown ML; Phillips SF; Go VL
    Gastroenterology; 1990 Jan; 98(1):111-6. PubMed ID: 2293569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ileal brake: neuropeptidergic control of intestinal transit.
    Van Citters GW; Lin HC
    Curr Gastroenterol Rep; 2006 Oct; 8(5):367-73. PubMed ID: 16968603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive measurement of transit time in short bowel syndrome.
    Compher C; Rubesin S; Kinosian B; Madaras J; Metz D
    JPEN J Parenter Enteral Nutr; 2007; 31(3):240-5. PubMed ID: 17463151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized double-blind crossover study to determine the effects of erythromycin on small intestinal nutrient absorption and transit in the critically ill.
    Deane AM; Wong GL; Horowitz M; Zaknic AV; Summers MJ; Di Bartolomeo AE; Sim JA; Maddox AF; Bellon MS; Rayner CK; Chapman MJ; Fraser RJ
    Am J Clin Nutr; 2012 Jun; 95(6):1396-402. PubMed ID: 22572649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.
    Iturrino J; Camilleri M; Acosta A; O'Neill J; Burton D; Edakkanambeth Varayil J; Carlson PJ; Zinsmeister AR; Hurt R
    JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1089-1095. PubMed ID: 26223941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
    Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
    Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study.
    Seguy D; Vahedi K; Kapel N; Souberbielle JC; Messing B
    Gastroenterology; 2003 Feb; 124(2):293-302. PubMed ID: 12557135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.